<DOC>
	<DOC>NCT02975674</DOC>
	<brief_summary>The trial is designed as a consecutive enrollment prospective one-center study. A minimum of 30 patients will be included in the study. At implant installation, the patient will be randomized to receive one of the two types of implants (Control: internal hexagon connection implants (CON.INT); Test: Morse taper connection implants (MT-12)). Samples of peri-implant crevicular fluid (PICF) and intrasulcular plaque will be collected at -21 (second-stage surgery), -14 (impressions), 0 (Baseline: prosthesis delivery), 7 days and 1, 3, 6, 12 months. Prosthesis will be fabricated and delivered as usual, i.e., approximately two weeks after the impressions are taken.</brief_summary>
	<brief_title>Evaluation of MT-12 Implant Survival and Marginal Bone Loss</brief_title>
	<detailed_description />
	<mesh_term>Jaw, Edentulous, Partially</mesh_term>
	<mesh_term>Jaw, Edentulous</mesh_term>
	<criteria>Patient &gt;18 and â‰¤75 years old One missing tooth in the premolar or molar area with both opposing and adjacent teeth (mesial and distal) Onestage bone augmentation Uncontrolled type 1 or 2 diabetes (HgA1c&gt;8) Known autoimmune or inflammatory disease Severe hematologic disorders, such as hemophilia or leukemia Local or systemic infection that may compromise normal healing (e.g., extensive periapical pathology) Liver or kidney dysfunction/failure Currently receiving cancer treatment or within 18 months from completion of radio or chemotherapy Longterm history of oral bisphosphonates use (i.e., 10 years or more) History of intravenous bisphosphonates Longterm (&gt;3 months) history of antibiotics or drugs known to alter the inflammation and/or immunological system 3 months before inclusion Severe osseous diseases (e.g., Paget disease of bone) Pregnant women or nursing mothers Not able or not willing to follow instructions related to the study procedures</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>